About Sinovant Sciences
Sinovant Sciences is a Shanghai-based biopharmaceutical company dedicated to bringing innovative medicines to China and advancing Chinese biopharmaceutical innovation abroad. Sinovant has built a pipeline of 11 investigational biopharmaceutical products for Greater China and other Asian markets, including four therapies suitable for Phase 3 clinical trial application or registration in China. Sinovant's investigational therapies address several of China's greatest public health priorities, including liver cancer and drug-resistant bacterial infections.
Latest Sinovant Sciences News
May 27, 2021
publication date: May 27, 2021 Sinovant Sciences, a China adults with community acquired bacterial pneumonia (CABP). The trial showed lefamulin was non-inferior to IV/oral moxifloxacin in patients with CABP. In 2017, Sinovant acquired China Vienna China Suzhou Share this with colleagues: Sorry this page is available to subscribers only. If you're not a subscriber why not subscribe today? If you are already a subscriber, please login. If you believe you should have received this message in error, please contact us .
Sinovant Sciences Frequently Asked Questions (FAQ)
When was Sinovant Sciences founded?
Sinovant Sciences was founded in 2017.
Where is Sinovant Sciences's headquarters?
Sinovant Sciences's headquarters is located at Shanghai.
What is Sinovant Sciences's latest funding round?
Sinovant Sciences's latest funding round is Corporate Majority.
Who are the investors of Sinovant Sciences?
Investors of Sinovant Sciences include Roivant Sciences and CPE.